RU2001110187A - METHOD FOR TREATING DISTURBED TOLERANCE FOR GLUCOSE - Google Patents

METHOD FOR TREATING DISTURBED TOLERANCE FOR GLUCOSE

Info

Publication number
RU2001110187A
RU2001110187A RU2001110187/14A RU2001110187A RU2001110187A RU 2001110187 A RU2001110187 A RU 2001110187A RU 2001110187/14 A RU2001110187/14 A RU 2001110187/14A RU 2001110187 A RU2001110187 A RU 2001110187A RU 2001110187 A RU2001110187 A RU 2001110187A
Authority
RU
Russia
Prior art keywords
compound
formula
administering
group
alkyl group
Prior art date
Application number
RU2001110187/14A
Other languages
Russian (ru)
Other versions
RU2281094C2 (en
Inventor
Джерольди ОЛЕФСКИ
Тэмми АНТОНУЧИ
Дин ЛОКВУД
Ребекка НОРРИС
Original Assignee
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед
Publication of RU2001110187A publication Critical patent/RU2001110187A/en
Application granted granted Critical
Publication of RU2281094C2 publication Critical patent/RU2281094C2/en

Links

Claims (9)

1. Способ лечения нарушенной толерантности к глюкозе с целью предотвращения или отдаления наступления инсулиннезависимого сахарного диабета у пациентов, страдающих нарушенной толерантностью к глюкозе, включающий введение пациенту, страдающему от данного заболевания, терапевтически эффективного количества соединения формулы (I)
Figure 00000001

где R1 и R2 одинаковые или разные, и каждый представляет атом водорода или C1-C5 алкильную группу;
R3 представляет атом водорода,
R4 и R5 одинаковые или разные, и каждый представляет атом водорода или C1-C5 алкильную группу;
n равно 1, 2 или 3;
W представляет группу формулы -СН2-; и
Y и Z одинаковые или разные, и каждый представляет атом кислорода или иминогруппу; или его фармацевтически приемлемой соли.1. A method of treating impaired glucose tolerance to prevent or delay the onset of non-insulin-dependent diabetes mellitus in patients suffering from impaired glucose tolerance, comprising administering to a patient suffering from this disease a therapeutically effective amount of a compound of formula (I)
Figure 00000001

where R 1 and R 2 are the same or different, and each represents a hydrogen atom or a C 1 -C 5 alkyl group;
R 3 represents a hydrogen atom,
R 4 and R 5 are the same or different, and each represents a hydrogen atom or a C 1 -C 5 alkyl group;
n is 1, 2 or 3;
W represents a group of the formula —CH 2 -; and
Y and Z are the same or different, and each represents an oxygen atom or an imino group; or a pharmaceutically acceptable salt thereof. 2. Способ по п. 1, включающий введение соединения формулы (I), где Y и Z являются кислородом. 2. A method according to claim 1, comprising administering a compound of formula (I), wherein Y and Z are oxygen. 3. Способ по п. 1, включающий введение соединения формулы (I), где n равно 1. 3. The method of claim 1, comprising administering a compound of formula (I), wherein n is 1. 4. Способ по п. 1, включающий введение соединения формулы (I), где каждый из R1, R2, R4 и R5 являются C1-C5 алкильной группой.4. The method of claim 1, comprising administering a compound of formula (I), wherein R 1 , R 2 , R 4, and R 5 are each a C 1 -C 5 alkyl group. 5. Способ по п. 1, включающий введение соединения формулы (I), где Z и Y являются кислородом и n равно 1. 5. The method of claim 1, comprising administering a compound of formula (I), wherein Z and Y are oxygen and n is 1. 6. Способ по п. 1, включающий введение соединения формулы (I), где соединением является (+)-5-[[4-[(3,4-дигидро-6-гидрокси-2,5,7,8-тетраметил-2Н-1-бензопиран-2-ил)метокси] фенил] метил] -2,4-тиазолидиндион. 6. The method of claim 1, comprising administering a compound of formula (I), wherein the compound is (+) - 5 - [[4 - [(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl -2H-1-benzopyran-2-yl) methoxy] phenyl] methyl] -2,4-thiazolidinedione. 7. Способ лечения нарушенной толерантности к глюкозе с целью предотвращения или отдаления наступления инсулиннезависимого сахарного диабета у пациентов, страдающих нарушенной толерантностью к глюкозе, включающий введение пациенту, страдающему от данного заболевания, терапевтически эффективного количества соединения формулы (II)
Figure 00000002

где R11 является фенильной группой, которая может быть необязательно замещена C1-C5 алкильной группой, С3-C6 циклоалкильной группой, которая может быть необязательно замещена C1-С5 алкильной группой или 5- или 6-членной гетероциклической группой, содержащей 1 или 2 гетероатома, выбранных из группы, включающей атомы азота, кислорода и серы, которая может быть необязательно замещена C1-C5 алкильной группой;
R12 является связью или алкиленовой группой, содержащей от 1 до 3 атомов углерода;
L1 и L2 одинаковые или разные, и каждый представляет атом водорода или C1-C5 алкильную группу, или его фармацевтически приемлемой соли.7. A method of treating impaired glucose tolerance in order to prevent or delay the onset of non-insulin-dependent diabetes mellitus in patients suffering from impaired glucose tolerance, comprising administering to a patient suffering from this disease a therapeutically effective amount of a compound of formula (II)
Figure 00000002

where R 11 is a phenyl group which may optionally be substituted with a C 1 -C 5 alkyl group, a C 3 -C 6 cycloalkyl group which may be optionally substituted with a C 1 -C 5 alkyl group or a 5- or 6-membered heterocyclic group, containing 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, which may optionally be substituted with a C 1 -C 5 alkyl group;
R 12 is a bond or alkylene group containing from 1 to 3 carbon atoms;
L 1 and L 2 are the same or different, and each represents a hydrogen atom or a C 1 -C 5 alkyl group, or a pharmaceutically acceptable salt thereof. 8. Способ по п. 7, включающий введение соединения формулы (II), где соединением является пиоглитазон. 8. The method of claim 7, comprising administering a compound of formula (II), wherein the compound is pioglitazone. 9. Способ по п. 7, включающий введение соединения формулы (II), где соединением является циглитазон. 9. The method of claim 7, comprising administering a compound of formula (II), wherein the compound is ciglitazone.
RU2001110187/14A 1993-09-15 2001-04-13 Method for treatment of impaired glucose tolerance RU2281094C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08/122,251 1993-09-15
US08/293,899 1994-08-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU96108256/14A Division RU2195282C2 (en) 1993-09-15 1994-09-14 Application of thiazolidinediones for prevention or onset postponement of insulin-independent diabetes mellitus (niddm)

Publications (2)

Publication Number Publication Date
RU2001110187A true RU2001110187A (en) 2003-03-10
RU2281094C2 RU2281094C2 (en) 2006-08-10

Family

ID=22401599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001110187/14A RU2281094C2 (en) 1993-09-15 2001-04-13 Method for treatment of impaired glucose tolerance

Country Status (22)

Country Link
US (3) US5457109A (en)
EP (2) EP0719143B1 (en)
JP (1) JPH09502722A (en)
KR (2) KR960704546A (en)
CN (1) CN1106195C (en)
AT (2) ATE198045T1 (en)
AU (1) AU678291B2 (en)
CA (1) CA2168751A1 (en)
CZ (3) CZ72296A3 (en)
DE (3) DE69426421T2 (en)
DK (2) DK0719143T3 (en)
ES (2) ES2154685T3 (en)
GR (1) GR3035430T3 (en)
HK (1) HK1085134A1 (en)
HU (1) HUT75873A (en)
NO (1) NO961052L (en)
NZ (2) NZ273806A (en)
PT (3) PT719143E (en)
RU (1) RU2281094C2 (en)
SG (1) SG67900A1 (en)
SK (1) SK35196A3 (en)
WO (1) WO1995007697A2 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046202A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of insulin resistance
ES2131301T3 (en) * 1993-12-27 1999-07-16 Japan Tobacco Inc DERIVED FROM ISOXAZOLIDINDIONA AND ITS USE.
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
ATE235476T1 (en) * 1994-08-10 2003-04-15 Takeda Chemical Industries Ltd THIAZOLIDINDIONE DERIVATIVES, THEIR PREPARATION AND USE
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
EP0851757A2 (en) * 1995-08-10 1998-07-08 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
JPH09323930A (en) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd Preventive and treating agent for cachexia
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) * 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
DE69738809D1 (en) * 1996-11-08 2008-08-14 Nippon Chemiphar Co MEANS FOR REDUCING OVEN FATS
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
WO1998042340A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
NZ501163A (en) 1997-06-18 2002-02-01 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US6265401B1 (en) * 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2307068C (en) 1997-10-27 2007-04-10 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
ATE325607T1 (en) * 1997-11-19 2006-06-15 Takeda Pharmaceutical APTOPTOSIS INHIBITORS
PL341293A1 (en) 1997-12-23 2001-04-09 Lilly Co Eli Beta-lypothropin and application thereof
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7528133B1 (en) * 1998-10-29 2009-05-05 The Board Of Regents Of The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
HUP0104303A3 (en) * 1998-11-12 2003-12-29 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DZ2937A1 (en) 1998-11-12 2004-03-15 Smithkline Beecham Plc New compositions of insulin sensitizers.
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6326396B1 (en) 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
TR200103061T2 (en) * 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
EA004541B1 (en) * 1999-04-23 2004-06-24 Смитклайн Бичам Плс Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
BR0017048A (en) * 1999-12-22 2002-11-05 Metabasis Therapeutics Inc Phosphonate bisamidate prodrugs
CA2406871A1 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
US6464959B1 (en) * 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
WO2001094410A1 (en) * 2000-06-08 2001-12-13 Metcon Medicin Ab Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
SE0002189D0 (en) 2000-06-09 2000-06-09 Metcon Medicin Ab New method and assay
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
KR200249057Y1 (en) * 2001-03-22 2001-10-19 김진환 Sewage backflow integrated into the lid and base. Odor Prevention Device
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7247702B2 (en) * 2002-02-28 2007-07-24 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
KR100450700B1 (en) * 2002-03-22 2004-10-01 주식회사종근당 Thiazolidinedione derivatives and pharmaceutical composition comprising the same
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US20040033954A1 (en) * 2002-08-15 2004-02-19 Sleeman Mark W. Therapeutic method for combined use of modified CNTF and thiadolidinedione
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
CN100344618C (en) 2004-05-24 2007-10-24 北京摩力克科技有限公司 N-benzyl acryloyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist
AU2005277479A1 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
WO2006101911A1 (en) 2005-03-16 2006-09-28 Case Western Reserve University Selective inhibitors of translesion dna replication
US9029345B2 (en) * 2005-03-16 2015-05-12 Case Western Reserve University Selective inhibitors of translesion DNA replication
US20080207711A1 (en) * 2007-02-28 2008-08-28 Rong Li Method for treating an ID2-related disorder
ES2344183B1 (en) * 2009-02-18 2011-06-10 Italfarmaco, S.A. USE OF INSULIN SENSITIZING AGENTS VIA VAGINAL.
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
US9988680B2 (en) 2011-09-01 2018-06-05 Case Western Reserve University Non-natural nucleosides as theranostic agents
US9192766B2 (en) 2011-12-02 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
US9750568B2 (en) * 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
AU2013340478B2 (en) 2012-11-05 2018-08-23 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
US9821173B2 (en) 2013-02-08 2017-11-21 Case Western Reserve University Anti-cancer agents and methods of use
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
HUE060167T2 (en) 2015-05-22 2023-02-28 Sulfateq Bv Compound for the prophylaxis or treatment of diabetic nephropathy or diabetic kidney disease
GB201518979D0 (en) * 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396392A (en) * 1977-02-01 1978-08-23 Kakenyaku Kako Kk Active substance for increasing secretion of insulin
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (en) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
CN1003445B (en) * 1984-10-03 1989-03-01 武田药品工业株式会社 The preparation method of thiazolidine diketone derivative
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (en) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Process for the preparation of benzoxazole derivatives as antidiabetic agents
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JP3544659B2 (en) * 1990-02-09 2004-07-21 ファルマシア・アンド・アップジョン・カンパニー Use of insulin sensitizers for the treatment of hypertension
JPH0469383A (en) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd Substituted thiazolidine derivative
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
JPH0725755B2 (en) * 1991-06-25 1995-03-22 ファイザー・インコーポレーテッド Thiazolidinedione hypoglycemic agent
EP0603419A4 (en) * 1992-07-13 1994-10-12 Japan Tobacco Inc Novel thiazolidinedione compound and use thereof.
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Similar Documents

Publication Publication Date Title
RU2001110187A (en) METHOD FOR TREATING DISTURBED TOLERANCE FOR GLUCOSE
KR960704544A (en) USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM to prevent or delay the onset of non-insulin dependent diabetes mellitus (NIDDM)
CA2533845A1 (en) Pharmaceutical compositions comprising insulin sensitivity enhancer and another antidiabetic
RU96108256A (en) APPLICATION OF THIAZOLIDINDIONES TO PREVENT OR DELAY THE ATTACK OF INSULIN INDEPENDENT DIABETES (NIDDM)
RU97119064A (en) APPLICATION OF ALPHA (IL) AGONISTS FOR THE TREATMENT OF URINE HOLDING
KR940006590A (en) Compounds useful for treating Alzheimer's disease and as hypoglycemic agents
JP2007501857A5 (en)
RU2002115263A (en) 5-membered N-heterocyclic compounds with hypoglycemic and lipid-lowering activity
KR930702287A (en) New compound
RU97114956A (en) METHOD OF INHIBITING INTER CELL ADHESION AND METHOD OF INHIBITING THE INFLAMMATORY PROCESS
RU96124376A (en) APPLICATION OF DERIVATIVES OF THIAZOLIDINE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
KR950701328A (en) Thiazole or imidazole derivatives as Maillard reaction inhibitors
RU2001127082A (en) AMINO DERIVATIVES
RU97109847A (en) DERIVATIVES OF AMINOTHETRAZOLE, USEFUL AS A NITROGEN OXIDE SYNTHASE INHIBITORS
JP2005526696A5 (en)
CA2232191A1 (en) Inhibition of tumor necrosis factor alpha
JP2002515427A5 (en)
RU2002117450A (en) New heterocyclic compounds and their salts and their use in medicine
RU2000123169A (en) BENZOTHIADIAZOLES AND THEIR DERIVATIVES
RU2004122427A (en) Pyrrolidin-2-ones as inhibitors of factor XA
NO991425L (en) Medical treatment
KR20000023719A (en) Novel Treatment of Leptine Resistance
HUP0003260A2 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
RU96103685A (en) 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION
RU98106104A (en) Pyrimidine derivatives